NextCure, Inc., a clinical-stage biopharmaceutical company focused on antibody-drug conjugates (ADCs) for oncology, is advancing Phase 1 trials for its lead candidates SIM0505 and LNCB74 with expected data readouts in 2026. The company reported consistent net losses around $56 million annually and an accumulated deficit exceeding $436 million as of FY2025, reflecting continued investment in R&D without commercial revenues. Cash and equivalents stood at approximately $26 million at year-end 2025, supporting operational runway into 2027 through cost controls and financing efforts. Strategic collaborations with Simcere Zaiming Pharmaceutical and LigaChem Biosciences broaden NextCure's pipeline while internal manufacturing was paused to conserve capital. Significant risks include ongoing intellectual property litigation involving senior management and regulatory compliance complexities that could impact commercialization timelines and funding access.